Kiviranta A-M, Laitinen-Vapaavuori O, Hielm-Björkman A, Jokinen T
Department of Equine and Small Animal Medicine, Faculty of Veterinary Medicine, University of Helsinki, FI-00014, Helsinki, Finland.
J Small Anim Pract. 2013 Oct;54(10):512-20. doi: 10.1111/jsap.12130. Epub 2013 Aug 23.
To evaluate the efficacy and safety of topiramate as an add-on therapy in dogs with refractory idiopathic epilepsy.
Prospective, open label, non-comparative clinical trial of topiramate in dogs with idiopathic epilepsy and poor seizure control despite therapeutic serum concentrations of phenobarbital and potassium bromide. The efficacy of topiramate was evaluated by comparing seizure and seizure day frequencies during a retrospective 2-month period with a prospective short-term follow-up of 6 months. An additional long-term follow-up period ranging from 3 to 9 months was conducted on dogs that responded to topiramate therapy during the short-term follow-up.
Ten dogs were included. Five (50%) responded to topiramate therapy during the short-term follow-up showing a significant (P=0·04) decrease of 66% in seizure frequency. Three of the five dogs remained responders during the long-term follow-up. Weight loss, sedation and ataxia were the most common adverse effects of topiramate therapy, but in dogs with moderate sedation or ataxia, signs subsided in a few weeks to few months to mild sedation or ataxia.
Topiramate may be effective as an add-on medication in treating canine idiopathic epilepsy. Apart from sedation and ataxia reported in some of the dogs, topiramate was well-tolerated.
评估托吡酯作为难治性特发性癫痫犬附加治疗的疗效和安全性。
对特发性癫痫且尽管苯巴比妥和溴化钾血清治疗浓度下癫痫发作控制不佳的犬进行托吡酯的前瞻性、开放标签、非对照临床试验。通过回顾性2个月期间与前瞻性6个月短期随访期间癫痫发作和癫痫发作日频率的比较来评估托吡酯的疗效。对在短期随访期间对托吡酯治疗有反应的犬进行了3至9个月的额外长期随访。
纳入10只犬。5只（50%）在短期随访期间对托吡酯治疗有反应，癫痫发作频率显著降低（P = 0·04），降低了66%。5只犬中有3只在长期随访期间仍有反应。体重减轻、镇静和共济失调是托吡酯治疗最常见的不良反应，但在有中度镇静或共济失调的犬中，症状在几周至几个月内消退为轻度镇静或共济失调。
托吡酯作为附加药物治疗犬特发性癫痫可能有效。除了部分犬出现的镇静和共济失调外，托吡酯耐受性良好。
Zotero 插件